These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19754359)

  • 1. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
    van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between IGF-1R and other tumor promoting pathways.
    Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y
    Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
    Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
    MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
    Hwang KA; Park MA; Kang NH; Yi BR; Hyun SH; Jeung EB; Choi KC
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):637-46. PubMed ID: 23933164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
    Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
    Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
    Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
    Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
    van der Meel R; Oliveira S; Altintas I; Haselberg R; van der Veeken J; Roovers RC; van Bergen en Henegouwen PM; Storm G; Hennink WE; Schiffelers RM; Kok RJ
    J Control Release; 2012 Apr; 159(2):281-9. PubMed ID: 22227023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
    Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
    MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer.
    Singh I; Amin H; Rah B; Goswami A
    Front Biosci (Schol Ed); 2013 Jan; 5(1):231-46. PubMed ID: 23277048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor.
    Adams TE; McKern NM; Ward CW
    Growth Factors; 2004 Jun; 22(2):89-95. PubMed ID: 15253384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
    Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
    Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
    Saxena NK; Taliaferro-Smith L; Knight BB; Merlin D; Anania FA; O'Regan RM; Sharma D
    Cancer Res; 2008 Dec; 68(23):9712-22. PubMed ID: 19047149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
    Tandon R; Senthil V; Nithya D; Pamidiboina V; Kumar A; Malik S; Chaira T; Diwan M; Gupta P; Venkataramanan R; Malik R; Das B; Dastidar SG; Cliffe I; Ray A; Bhatnagar PK
    Eur J Pharmacol; 2013 Jul; 711(1-3):19-26. PubMed ID: 23639757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
    Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H
    Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.
    van der Meel R; Oliveira S; Altintas I; Heukers R; Pieters EH; van Bergen en Henegouwen PM; Storm G; Hennink WE; Kok RJ; Schiffelers RM
    Mol Pharm; 2013 Oct; 10(10):3717-27. PubMed ID: 23889133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.